Biomarkers of acute myocardial infarction: diagnostic and prognostic value. Part 2 (Literature review)

Biomarkers of acute myocardial infarction: diagnostic and prognostic value. Part 2 (Literature review)

In the second part of the review, we continue the discussion of biomarkers that have a diagnostic and prognostic significance in acute myocardial infarction (AMI). The study of the AMI pathophysiology through the experimental and clinical research contributes to the discovery of new regulatory molec...

Full description

Bibliographic Details
Main Authors:	Aleksey M. Chaulin, Dmitry V. Duplyakov
Format:	Article
Language:	English
Published:	Eco-vector 2020-12-01
Series:	Клиническая практика
Subjects:	laboratory diagnostics acute myocardial infarction ami biomarkers c-reactive protein interleukin-6 tumor necrosis factor-alpha myeloperoxidase matrix metalloproteinases procalcitonin microribonucleic acids galectin-3 proprotein convertase subtilisin-kexin type 9
Online Access:	https://journals.eco-vector.com/clinpractice/article/viewFile/48893/pdf

Similar Items

Levels of proprotein convertase subtilisin/kexin type 9 in patients with acute myocardial infarction
by: A. D. Gimadeeva, et al.
Published: (2020-03-01)

Prognostic Impacts of LL-37 in Relation to Lipid Profiles of Patients with Myocardial Infarction: A Prospective Cohort Study
by: Runzhen Chen, et al.
Published: (2022-10-01)

New groups of hypolipidemic drugs based on inhibition of proprotein convertase subtilisin/kexin type 9 (PCSK9). Part 1
by: Aleksey M. Chaulin, et al.
Published: (2021-03-01)

PCSK9 in acute coronary syndrome: analysis of associations with clinical and laboratory characteristics
by: Yu. A. Drenina, et al.
Published: (2020-09-01)

ASSOCIATION OF POLYMORPHISM IN PCSK9 GENE WITH LIPID PR OFILE IN RUSSIAN POPULATION
by: K. S. Astrakova, et al.
Published: (2016-06-01)

Analysis of Influencing Factors of Plasma Proprotein Convertase Subtilisin/Kexin Type 9 in Patients with Acute Myocardial Infarction
by: JIA Jia, LIU Jiahui, JI Wenjun, ZHENG Bo, WANG Xingang, FAN Fangfang, LI Yin, ZHANG Long, ZHANG Yan
Published: (2024-12-01)

Proprotein convertase subtilisin/kexin type 9 inhibitors: prospects for cholesterol-lowering therapy in type 2 diabetes
by: V.A. Serhiyenko, et al.
Published: (2023-03-01)

ASSOCIATION OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 WITH HYPERTENSION AND SMOKING
by: K. S. Benimetskaya, et al.
Published: (2019-03-01)

Efficacy of Alirocumab, Evolocumab, and Inclisiran in Patients with Hypercholesterolemia at Increased Cardiovascular Risk
by: Renata Rajtar-Salwa, et al.
Published: (2024-07-01)

Evolocumab loaded Bio-Liposomes for efficient atherosclerosis therapy
by: Zhenxian Li, et al.
Published: (2023-05-01)

Association of the PCSK6 rs1531817(C/A) polymorphism with the prognosis and coronary stenosis in premature myocardial infarction patients: a prospective cohort study
by: Li Sun, et al.
Published: (2024-07-01)

Integrated bioinformatics analysis identifies PCSK9 as a prognosticator correlated with lipid metabolism in pancreatic adenocarcinoma
by: Siqi Zhou, et al.
Published: (2024-09-01)

Evaluation of adropin indices and PCSK9 in non-diabetic men with severe obstructive sleep apnea
by: Deniz Levent, et al.
Published: (2024-06-01)

The Impact of PCSK9 Gene Polymorphisms on Ischemic Stroke: A Systematic Review and Meta-Analysis
by: Jianhong Wang, et al.
Published: (2024-03-01)

Effect of Evolocumab on Lipoprotein(a) and PCSK9 in Healthy Individuals with Elevated Lipoprotein(a) Level
by: Olga Afanasieva, et al.
Published: (2020-10-01)

Towards Developing Novel Prostate Cancer Recurrence Suppressors: Acute Toxicity of Pseurotin A, an Orally Active PCSK9 Axis-Targeting Small-Molecule in Swiss Albino Mice
by: Oliver C. McGehee, et al.
Published: (2023-02-01)

PCSK9 gene participates in the development of primary dyslipidemias
by: Matías-Pérez D, et al.
Published: (2021-07-01)

Clinical studies of monoclonal antibodies against the proprotein convertase subtilisin / kexin type 9
by: K. S. Astrakova, et al.
Published: (2015-06-01)

Guideline LDL-C Threshold Achievement in Acute Myocardial Infarction Patients: A Real-World Evidence Study Demonstrating the Impact of Treatment Intensification with PCSK9i
by: Erin S. Mackinnon, et al.
Published: (2023-01-01)

RETRACTED ARTICLE: Potential use of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition and prevention method in viral infection
by: Khursheed Muzammil, et al.
Published: (2024-03-01)

Blocking cholesterol formation and turnover improves cellular and mitochondria function in murine heart microvascular endothelial cells and cardiomyocytes
by: Alicja Braczko, et al.
Published: (2023-09-01)

Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in the treatment of dyslipidemia
by: A. A. Shikaleva, et al.
Published: (2021-01-01)

Silencing hepatic PCSK9 via novel chimeric AAV8 mitigates the progression of atherosclerosis by inhibiting inflammation in ApoE−/− mice
by: Xiaocui Chen, et al.
Published: (2025-03-01)

PCSK9 affects vascular senescence through the SIRT1 pathway
by: Yuqin Wang, et al.
Published: (2025-03-01)

Safety and efficacy of PCSK9 inhibitors and effect on coronary plaque phenotype in statin-treated patients following acute coronary syndrome: a systematic review and meta-analysis
by: Dennis Ievan Hakim, et al.
Published: (2024-10-01)

Rationale for Early Administration of PCSK9 Inhibitors in Acute Coronary Syndrome
by: Salvatore Giordano, et al.
Published: (2024-10-01)

Familial Hypercholesterolemia
by: FENG Siqin, et al.
Published: (2023-01-01)

Evolocumab, a PCSK9‐Monoclonal Antibody, Rapidly Reverses Coronary Artery Endothelial Dysfunction in People Living With HIV and People With Dyslipidemia
by: Thorsten M. Leucker, et al.
Published: (2020-07-01)

Proteomics and Lipidomics to unveil the contribution of PCSK9 beyond cholesterol lowering: a narrative review
by: Erica Gianazza, et al.
Published: (2023-06-01)

Loss of Hepatic Surf4 Depletes Lipid Droplets in the Adrenal Cortex but Does Not Impair Adrenal Hormone Production
by: Xiaole Chang, et al.
Published: (2021-11-01)

Corrigendum: Loss of hepatic Surf4 depletes lipid droplets in the adrenal cortex but does not impair adrenal hormone production
by: Xiaole Chang, et al.
Published: (2023-05-01)

PCSK9 deficiency alters brain lipid composition without affecting brain development and function
by: Angela Pärn, et al.
Published: (2023-01-01)

The rs508487, rs236911, and rs236918 Genetic Variants of the Proprotein Convertase Subtilisin–Kexin Type 7 (<i>PCSK7</i>) Gene Are Associated with Acute Coronary Syndrome and with Plasma Concentrations of HDL-Cholesterol and Triglycerides
by: Gilberto Vargas-Alarcón, et al.
Published: (2021-06-01)

Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Beyond Lipids: The Role in Oxidative Stress and Thrombosis
by: Vittoria Cammisotto, et al.
Published: (2022-03-01)

PCSK9 with a gain of function D374Y mutation aggravates atherosclerosis by inhibiting PPARα expression
by: Yuan feng Cui, et al.
Published: (2025-02-01)

The importance of paying attention to the role of lipid-lowering drugs in controlling dengue virus infection
by: Omer Qutaiba B. Allela, et al.
Published: (2024-12-01)

PCSK9 Inhibitors: The Evolving Future
by: Bijay Mukesh Jeswani, et al.
Published: (2024-11-01)

Association of lipid-lowering drug targets with risk of cutaneous melanoma: a mendelian randomization study
by: Lusheng Miao, et al.
Published: (2024-05-01)

Sex difference in circulating PCSK9 and its clinical implications
by: Fang Jia, et al.
Published: (2022-09-01)

Novel insights into the association between genetically proxied inhibition of proprotein convertase subtilisin/kexin type 9 and risk of sarcopenia
by: Hongyan Jiang, et al.
Published: (2024-12-01)